Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

Conditions

• Type 2 Diabetes Mellitus

Eligibility Criteria

Sex

ALL

Age

18 Years - 77 Years

Healthy Volunteers

Not accepted

Interventions

• Evolocumab — DRUG

Study Details

Postprandial lipemia is highly prevalent in type 2 diabetes subjects even with normal fasting triglyceride values. Humans are mostly in a postprandial rather than in a fasting state and therefore non-fasting triglyceride values reflect more accurately the continuous exposure of arterial wall to the substantial cholesterol load from remnant particles. Evolocumab lowers blood LDL-cholesterol. This study evaluates the effect of evolocumab on postprandial lipid metabolism in type 2 diabetes. All participants in this study receive evolocumab treatment.

Key Dates

First listed

Oct 28, 2016

Start date

Oct 31, 2016

Status verified

Oct 2021

Primary completion

Jun 30, 2018

Completion

Jun 30, 2018

Study Design

Enrollment

14 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Evolocumab
  Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks

Primary Outcome Measure

Mean ApoB Concentration Before and After Evolocumab [ Time Frame: Baseline and after 12 weeks ]

Find similar trials

Related Studies

• Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
  Recruiting · Petter Bjornstad · Aurora, Colorado
• A Study of Glycemic Control in Left Ventricular Assist
  Recruiting · Mayo Clinic · Rochester, Minnesota
• An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
  Recruiting · Bayer · Multiple Locations, New Jersey
• A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
  PHASE3 · Not Yet Recruiting · Oramed, Ltd. · Dallas, Texas